No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 19
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for AN2 Therapeutics, Inc. (ANTX) stock was $5.61 as of Oct 5, 2026, 4:00 PM EDT, down 1.75% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +328.5% · 3-year avg -28.2%/yr
AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions.
Biotechnology · Menlo Park, CA
Next Earnings Date
Nov 5, 2026
30 days away
EPS Estimate
-0.20
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.18
vs Estimate
$-0.24
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ANTX | $202.05M | $5.61 | -1.75% | +328.54% | N/A | N/A | N/A |
| 2ETRA | $206.61M | $9.74 | -6.08% | N/A | N/A | N/A | vs ANTX |
| 3ELDN | $192.97M | $2.50 | +0.40% | -11.92% | -15.17% | -37.18% | vs ANTX |
| 4CGEN | $218.42M | $2.31 | +0.00% | +41.48% | -18.39% | -9.42% | vs ANTX |
| 5DERM | $184.12M | $6.69 | +1.21% | -8.69% | N/A | N/A | vs ANTX |
| 6ALEC | $220.94M | $1.99 | +9.94% | -39.91% | -39.17% | N/A | vs ANTX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 2 analysts
Average Price Target
$9.00
+60.4% upside
Low
$9.00
Current
$5.61
High
$9.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Quarter ending Dec 2026 | $-0.26 | $-0.23 | $-0.21 | 2 |
| Quarter ending Mar 2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Quarter ending Jun 2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.90 | $-0.90 | $-0.90 | 1 |
| FY 2027 | $-0.80 | $-0.80 | $-0.80 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $72.70M | $72.70M | $72.70M | 2 |
| FY 2027 | $217.00M | $217.00M | $217.00M | 2 |
